You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
Merck's Phase 3 trial of sac-TMT meets overall survival endpoint in advanced gastroesophageal cancer
20 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that the Phase 3 TroFuse-015 trial evaluating investigational drug sacituzumab tirumotecan (sac-TMT) met its prima...
20 November 2026 - Biotechnology company BioMimetix JV LLC announced on Thursday the publication of results from a multicentre Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiati...
20 November 2026 - Interlude Biopharma Co, a late-stage, drug-development company focused on celiac disease, announced on Thursday the company's public launch at the 21st International Celiac Disease Symposium (ICDS 2026) and introduced plans fo...
19 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that it has entered into a strategic research collaboration with Isomorphic Labs, an AI-first drug design and de...
19 November 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that it has received European Commission approval for VaxRabeo, its next-generation rabies vaccine, for pre-exposure and post-exposure pr...
19 November 2026 - Life sciences company Avacta Therapeutics (AIM:AVCT) on Thursday reported new preclinical data showing that its investigational cancer drug AVA6207 overcame resistance to topoisomerase I inhibitors (TOP1i) in laboratory studies and...
19 November 2026 - Biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Wednesday that it will work with Curia Global, a contract development and manufacturing organisation (CDMO), to provide formulation development services for Ani...